NCT01307605 is a Phase 2 clinical trial of Rituximab in Lymphoma, sponsored by Swiss Cancer Institute.

Who is sponsoring NCT01307605?

NCT01307605 is sponsored by Swiss Cancer Institute.

What drugs are being tested in NCT01307605?

Interventions in NCT01307605: Rituximab, lenalidomide.

Is NCT01307605 still recruiting?

NCT01307605 is currently terminated. Last updated 27 June 2023.

Last reviewed 2023-06-27 · How we verify

NCT01307605

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma

Terminated Phase 2 Last updated 27 June 2023

What this trial tests

Phase 2 trial testing Rituximab in Lymphoma in 154 participants. Terminated before completion.

Timeline

9 February 2011

Primary endpoint
20 June 2014

25 January 2023

Quick facts

Lead sponsor	Swiss Cancer Institute
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	154
Start date	9 February 2011
Primary completion	20 June 2014
Estimated completion	25 January 2023
Sites	33 locations across Sweden, Switzerland, Norway

Drugs / interventions tested

Rituximab — full drug profile →
lenalidomide — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

Swiss Cancer Institute

Who can join

18 and older, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Lenalidomide may stop the growth of non-Hodgkin lymphoma by blocking blood flow to the cancer. It is not yet known whether rituximab is more effective when given alone or together with lenalidomide in treating patients with follicular lymphoma. PURPOSE: This randomized phase II trial is studying rituximab to see how well it works compared with giving rituximab together with lenalidomide in treating patients with previously untreated follicular lymphoma.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
Gribben JG, Fowler N, Morschhauser F. · · 2015 · cited 231× · PMID 26195701 · DOI 10.1200/jco.2014.59.5363
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
Zucca E, Rondeau S, Vanazzi A, Østenstad B, et al · · 2019 · cited 42× · PMID 31101627 · DOI 10.1182/blood-2018-10-879643
Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy.
Menter T, Tzankov A, Zucca E, Kimby E, et al · · 2020 · cited 16× · PMID 32012230 · DOI 10.1111/bjh.16414
Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma.
Strati P, Jain P, Johnson RJ, Forbes S, et al · · 2021 · cited 11× · PMID 32932518 · DOI 10.1182/blood.2020007994
Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma.
Liu Y, Li Y, Zhang C, Yang X, et al · · 2024 · cited 1× · PMID 38578513 · DOI 10.1007/s12672-024-00965-7

Verify or expand the search:

Other trials of Rituximab

Trials testing the same drug.

NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT06965114 — Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia · Phase 1, PHASE2 · recruiting
NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Swiss Cancer Institute trials

Trials by the same sponsor.

NCT07158489 — Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC · Phase 2 · not yet recruiting
NCT06835049 — Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue · Phase 2 · recruiting
NCT06452394 — NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline · Phase 2 · recruiting
NCT06114108 — Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients · NA · recruiting
NCT04629781 — Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01307605 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swiss Cancer Institute
Last refreshed: 27 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01307605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing